Figure S5 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer | Synapse
September 16, 2025
Figure S5 from Combination of the MTA-Cooperative PRMT5 Inhibitor BMS-986504 and KRAS Inhibitors Is an Effective Treatment Strategy for MTAP-Deleted KRAS-Mutant Pancreatic Cancer
Key Points
Combination treatment significantly enhances efficacy against pancreatic cancer cells lacking MTAP.
Analysis showed synergistic effects between PRMT5 inhibitors and KRAS inhibitors in vitro.
This approach opens new avenues for targeted therapies in specific pancreatic cancer genotypes.
Further studies are necessary for clinical validation and effectiveness assessments in human trials.
Abstract
Figure S5 shows PRMT5i and pan-RASi combination treatment analysis in vitro.
AI에게 질문
Like
Bookmark
Share
Cite This Study
Drizyte‐Miller et al. (Mon,) studied this question.